As of July 8, 2013 - protocols do open and close daily.
Please check with your physician for additional protocols and/or information.
1. GOG 0249: A Phase III Trial of Pelvic RT vs. Vaginal Cuff Brachytherapy Followed by Paclitaxel/ Carboplatin Chemotherapy in Patients with High Risk Early Stage Endometrial Carcinoma
In this study you will receive either radiation therapy to the pelvis (standard of care) or vaginal radiation therapy combined with 3 cycles of the chemotherapy drugs paclitaxel and carboplatin (investigational). You will not get both.
The purpose of this study is to compare the effects of radiation therapy to the pelvis with vaginal radiation therapy combined with 3 cycles of the chemotherapy drugs paclitaxel and carboplatin on you and your high-risk endometrial cancer to find out which works better in reducing the chance that your cancer comes back. The pelvic radiation therapy (Regimen I) is considered standard of care. In addition, this study will compare survival, side effects, and differences in where the cancer may recur in patients treated with one of the two treatments. The study will also look at how a patient’s overall health and weight impact how well patients do and how these factors affect a patient’s quality of life. This study is also interested in testing samples of your tumor tissue (if available form a previous surgery) and blood to determine if this testing can be used in the future to determine which patients may respond to treatment or have a good prognosis.
2. GOG 0262: Randomized Phase III Trial of Every 3 Weeks Paclitaxel vs. Dose Dense Weekly Paclitaxel in Combination with Caboplatin + Cuncurrent & Consolidation Bevacizumab in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
The current standard treatment for ovarian, fallopian tube, and primary peritoneal cancer is a combination of chemotherapy drugs, carboplatin and paclitaxel, given every three weeks. Recently, investigators have shown that giving paclitaxel every week can increase the length of time without disease; however, there was more anemia (low red blood cell count) associated with this treatment. The purpose of this study is to compare the effectiveness and side effects of paclitaxel given every three weeks versus paclitaxel given once a week, when combined with carboplatin. Both chemotherapy treatments will be given for six cycles.
For more information on these protocols or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133